Patent ID: 11911469
Assignee: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. The method of claim 1, wherein:
the ACAT1 inhibitor is selected from the group consisting of avasimibe (CI-1011), pactimibe, purpactins, manassantin A, glisoprenin A, CP113,818, K604, beauveriolide I, beauveriolide III, TMP-153, YM750, GERI-BP002-A, Sandoz Sah 58-035, VULM 1457, CI976, CL-283,546, CI-999, E5324, YM17E, FR182980, ATR-101 (PD132301 or PD132301-2), F-1394, HL-004, F-12511 (eflucimibe), Dup 128, RP-73163, pyripyropene C, FO-1289, AS-183, SPC-15549, FO-6979, Angekica, ginseng, Decursin, terpendole C, beauvericin, spylidone, pentacecilides, CL-283,546, betulinic acid, esculeogenin A, Wu-V-23, pyripyropene A, B, and D, glisoprenin B-D, saucerneol B, sespendole, diethyl pyrocarbonate, beauveriolide analogues, Acaterin, DL-melinamide, PD 138142-15, CL277,082, EAB-309, Enniatin antibiotics, Epi-cochlioquinone A, FCE-27677, FR186485, FR190809, NTE-122, obovatol, panaxadiols, protopanaxadiols, polyacetylenes, SaH 57-118, AS-186, BW-447A, 447C88, T-2591, TEI-6522, TEI-6620, XP 767, XR 920, GERI-BP001, gomisin N, gypsetin, helminthosporol, TS-962, isochromophilones, kudingosides, lateritin, naringenin, and combinations thereof; and
the immune checkpoint inhibitor is an anti-PD-1 or anti-PD-L1 antibody.